Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (GVHD)
US9867843B2 · kind B2 · utility
3Cited by
28References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 1, 2016 |
| Grant date | Jan 16, 2018 |
| Priority date | — |
| Expiry date | Dec 1, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/111
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.